Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland.
Thomas M CaparrottaLuke A K BlackbournStuart J McGurnaghanJohn ChalmersRobert S LindsayRory J McCrimmonJohn McKnightSarah D WildJohn R PetrieSam PhilipPaul M McKeigueDavid J WebbNaveed SattarHelen Martina Colhounnull nullPublished in: Diabetes care (2020)
Thus, 80,830 (30.4%) of all those with T2D (n = 265,774) would start one of these drug classes according to table 7 and figure 3 of the guideline. The sizeable impact on drug budgets, enhanced clinical monitoring, and the trade-off with reduced CVD-related health care costs will need careful consideration.